Catabasis touts early-stage results; Troubled Merck focuses on sleep drug;

 @FierceBiotech: Sanofi move to acquire more shares of Regeneron triggers market buzz. Report | Follow @FierceBiotech

@JohnCFierce: Tresiba news underscores how high the FDA sets the bar on diabetes. Hard for biotechs to play in a field like this. News | Follow @JohnCFierce

@RyanMFierce: 'Mercenary' coders crowd-sourced for immunology research software. Report | Follow @RyanMFierce

> Catabasis says that its Omega-3 therapy performed well in a slate of Phase I studies, demonstrating signs of efficacy against an inflammatory biomarker. Story

> With several of its late-stage development programs in trouble, analysts increasingly expect Merck's ($MRK) future to be closely tied to the fate of the sleep drug Suvorexant, now under regulatory review. Report

> A number of organizations in Scotland are getting involved with the 5-year European Lead Factory initiative. Story

Pharma News

@FiercePharma: Corks pop at Sanofi as FDA nixes Novo's Lantus challenger. Article | Follow @FiercePharma

@EricPFierce: New Celgene drug for multiple myeloma expected to help fuel expansion of market to $7.2 billion. News | Follow @EricPFierce

@AlisonBFierce: A genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival more than a year. More | Follow @AlisonBFierce

> FDA hearing on opioids reflects evolving view on painkiller use. Report

> Will NIH data win Avastin a new use in cervical cancer? Story

Medical Device News

 @FierceMedDev: Israeli team advances genetic device to perform DNA diagnosis. Report | Follow @FierceMedDev

 @MarkHFierce: Indiana offers a way to work around the device tax, rather than focusing on repealing it. More | Follow @MarkHFierce

 @DamianFierce: Pfizer's ongoing R&D slash and burn could be good news for CROs. Story | Follow @DamianFierce

> Japan's regulators push for quicker device approval process. News

> Indiana mulls industry tax break to counter federal device tax. Report

CRO News

> GSK ups the ante for trial transparency. Story

> Struggling Cardiome recruits Quintiles to handle heart drug. More

> Struggling Cardiome recruits Quintiles to handle heart drug. News

> QPS snags Florida trial site amid buying spree. Report

> Pfizer's Singapore slash and burn could be good news for CROs. Article

Biotech IT News

> Trials software outfit BioClinica reports annual results (for the last time?) Item

> Sanofi backs mobile service for cancer patients on chemo. News

> 'Mercenary' coders crowd-sourced for immunology research software. Report

> Biotech, pharma warming up to Facebook. Article

> Eli Lilly's virtual unit taps Oracle software for clinical trials. Story

And Finally… Investigators report that removing a protein called Gfi1 from leukemic cells made them particularly vulnerable to chemo and radiation in animal studies, offering a new approach to treating leukemia. Release

 

Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.